{"id":1068196,"date":"2022-04-01T02:09:12","date_gmt":"2022-04-01T06:09:12","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/io-biotech-announces-year-end-results-for-2021\/"},"modified":"2024-08-18T11:44:10","modified_gmt":"2024-08-18T15:44:10","slug":"io-biotech-announces-year-end-results-for-2021","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/io-biotech-announces-year-end-results-for-2021.php","title":{"rendered":"IO Biotech Announces Year-End Results for 2021"},"content":{"rendered":"<p><![CDATA[--Updated Data from Phase 1\/2 study of IO102-IO103 in Combination with Nivolumab Showing High Response Rates in Metastatic Melanoma to be Presented at AACR in April---- Began Patient Recruitment for Global Phase 3 Combination Trial with Lead Asset IO102-IO103 and KEYTRUDA\u00ae (pembrolizumab) as First-Line Treatment in Advanced Melanoma--]]><\/p>\n<p>More:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/news-release\/2022\/03\/31\/2414386\/0\/en\/IO-Biotech-Announces-Year-End-Results-for-2021.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"IO Biotech Announces Year-End Results for 2021\">IO Biotech Announces Year-End Results for 2021<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>More: IO Biotech Announces Year-End Results for 2021 <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/io-biotech-announces-year-end-results-for-2021.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-1068196","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068196"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1068196"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068196\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1068196"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1068196"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1068196"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}